Isolation and therapeutic potential of human haemopoietic stem cells

被引:8
作者
Clark, AD
Jorgensen, HG
Mountford, J
Holyoake, TL [1 ]
机构
[1] Univ Glasgow, Royal Infirm, Div Canc Sci & Mol Pathol, Glasgow, Lanark, Scotland
[2] Univ Glasgow, Canc Res Beatson Labs, Glasgow, Lanark, Scotland
[3] N Glasgow Hosp Univ Trust, Royal Infirm, Dept Haematol, Glasgow, Lanark, Scotland
关键词
embryonic stem cells; gene therapy; haemopoietic stem cells; MAPC; mesenchymal stem cells; stem cell transplantation;
D O I
10.1023/A:1024822722285
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];
摘要
The haemopoietic stem cell (HSC) has long been regarded as an archetypal, tissue specific, stem cell, capable of completely regenerating haemopoiesis after myeloablation. It has proved relatively easy to harvest HSC, from bone marrow or peripheral blood. In turn, isolation of these cells has allowed therapeutic stem cell transplantation protocols to be developed, that capitalise on their prodigious self renewal and proliferative capabilities. Ex vivo approaches have been described to isolate, genetically manipulate and expand pluripotent stem cell subsets. These techniques have been crucial to the development of gene therapy, and may allow adults to enjoy the potential advantages of cord blood transplantation. Recently, huge conceptual changes have occurred in stem cell biology. In particular, the dogma that, in adults, stem cells are exclusively tissue restricted has been questioned and there is great excitement surrounding the potential plasticity of these cells, with the profound implications that this has, for developing novel cellular therapies. Mesenchymal stem cells, multipotent adult progenitor cells and embryonic stem cells are potential sources of cells for transplantation purposes. These cells may be directed to produce HSC, in vitro and in the future may be used for therapeutic, or drug development, purposes.
引用
收藏
页码:111 / 131
页数:21
相关论文
共 241 条
[1]
IDENTIFICATION IN ADULT BONE-MARROW OF PLURIPOTENT AND RESTRICTED STEM-CELLS OF MYELOID AND LYMPHOID SYSTEMS [J].
ABRAMSON, S ;
MILLER, RG ;
PHILLIPS, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 145 (06) :1567-1579
[2]
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning [J].
Aiuti, A ;
Slavin, S ;
Aker, M ;
Ficara, F ;
Deola, S ;
Mortellaro, A ;
Morecki, S ;
Andolfi, G ;
Tabucchi, A ;
Carlucci, F ;
Marinello, E ;
Cattaneo, F ;
Vai, S ;
Servida, P ;
Miniero, R ;
Roncarolo, MG ;
Bordignon, C .
SCIENCE, 2002, 296 (5577) :2410-2413
[3]
The number of CD34+ cells mobilized into the peripheral blood can predict the quality of subsequent collections [J].
Alcorn, MJ ;
Farrell, E ;
Barr, J ;
Pearson, C ;
Green, R ;
Holyoake, T .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (01) :89-93
[4]
Ex vivo expansion of haemopoietic progenitor cells [J].
Alcorn, MJ ;
Holyoake, TL .
BLOOD REVIEWS, 1996, 10 (03) :167-176
[5]
Evaluation of serum-free culture conditions able to support the ex vivo expansion and engraftment of human hematopoietic stem cells in the human-to-sheep xenograft model [J].
Almeida-Porada, G ;
Brown, RL ;
MacKintosh, FR ;
Zanjani, ED .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (05) :683-693
[6]
ANDREWS RG, 1994, BLOOD, V84, P800
[7]
Haploidentical stem cell transplantation in leukemia [J].
Aversa, F ;
Velardi, A ;
Tabilio, A ;
Reisner, Y ;
Martelli, MF .
BLOOD REVIEWS, 2001, 15 (03) :111-119
[8]
Bai LY, 2000, ONCOL REP, V7, P33
[9]
Ball SE, 1998, BLOOD, V91, P3582
[10]
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48